• Home
  •  / 
  • News
  •  / 
  • Lipobay (Cerivastatin)
News

Lipobay (Cerivastatin)

Lipobay (cerivastatin) was prescribed in the UK for lowering cholesterol levels. It was withdrawn in the UK by the manufacturer, Bayer, on 8 August 2001, following reports of side effects of rhabdomyolysis (muscle breakdown) which can lead to kidney failure.

Bayer currently face over 11,000 claims and in the USA they have already paid $614 million to settle 1,683 cases out of court.

If you would like to contact us for advice or discuss a possible claim then please contact us.

Press enquiries: Please click here to visit the press office

This news section contains stories of interest to our clients from PA Business and from publicly available news sources. Where we are representing the clients referred to in the news material we will say so. Where we do not represent individuals or bodies mentioned or quoted, the inclusion of the news story in our news section is not intended nor should it be taken to imply that we act for the individual or body concerned.

Make an enquiry
Talk to someone now - call 0870 1500100
News
Our recent work
Irwin Mitchell © 2008
The Lawyer 2006 Paralegal Awards Winner Level Double-A conformance icon, W3C-WAI Web Content Accessibility Guidelines 1.0 Personal Injury logo Investors In People logo Rehabilitation First Awards 2008 Winner SGS Peronal Injury Awards 08 Winner